For the first time, combining the AstraZeneca vaccine with Sputnik V results in “no serious adverse effects”: RDIF
The Russian Direct Investment Fund (RDIF) announced on Friday that the combination of the AstraZeneca vaccine and the first component of the Sputnik V vaccine had no serious side effects in the volunteers. The trial began in February in Azerbaijan and involved 50 people.
SII has already received cell and vector samples from the Gamaleya Center as part of the technology transfer, according to RDIF CEO Dmitriev. He also stated that the Drug Controller General of India has approved their import.
Dmitriev added that the agency is excited to work with the world’s largest vaccine manufacturer in regards to the agreement with SII.
This partnership, he said, is a significant step toward significantly increasing our production capabilities, and it serves as an excellent example of combining forces and expertise to save lives.
Previously, RDIF had vaccine production agreements with a number of pharmaceutical companies in India. The Sputnik V vaccine is now available in 67 countries around the world, with a total population of over 3.5 billion people.
RDIF, Russia’s sovereign wealth fund, and SII have also announced a partnership in India to manufacture the Russian Sputnik coronavirus vaccine. The first batch of vaccines will be produced at SII’s facilities in September, and the two companies plan to produce over 300 million doses of vaccine in India each year.
